Galectin Therapeutics Inc (GALT)

03:08 AM

Is Galectin Therapeutics Inc. stock resilient to inflationJuly 2025 Review & Precise Swing Trade Entry Alerts - ulpravda.ru

03:08 AM

01:09 AM

Will Galectin Therapeutics Inc. stock benefit from automation2025 Technical Overview & Community Consensus Trade Alerts - ulpravda.ru

01:09 AM

11:17 AM

Is Galectin Therapeutics Inc. stock attractive for income investors2025 Growth vs Value & High Win Rate Trade Tips - ulpravda.ru

11:17 AM

09:22 AM

Institution Moves: Will Galectin Therapeutics Inc. (PHPN) stock beat Nasdaq index returnsJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru

09:22 AM

Jan 07, 2026

Market Trends: Will Galectin Therapeutics Inc PHPN stock beat Nasdaq index returnsJuly 2025 Retail & Real-Time Volume Analysis Alerts - moha.gov.vn

Jan 07, 2026

Jan 07, 2026

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Jan 07, 2026

Jan 07, 2026

Galectin Therapeutics CFO sells $233k in shares - Investing.com

Jan 07, 2026

Jan 06, 2026

Insider Sell: Jack Callicutt Sells 60,000 Shares of Galectin Therapeutics Inc (GALT) - GuruFocus

Jan 06, 2026

Jan 06, 2026

Khurram Jamil Sells 21,446 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat

Jan 06, 2026

Jan 06, 2026

Galectin Therapeutics (NASDAQ:GALT) CFO Sells $58,438.80 in Stock - MarketBeat

Jan 06, 2026

Jan 06, 2026

Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CEO Sells 18,571 Shares of Stock - MarketBeat

Jan 06, 2026

Jan 06, 2026

Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock - MarketBeat

Jan 06, 2026

Jan 06, 2026

Galectin Therapeutics (NASDAQ:GALT) Insider Khurram Jamil Sells 13,055 Shares - MarketBeat

Jan 06, 2026

Jan 06, 2026

Insider Selling: Galectin Therapeutics (NASDAQ:GALT) CFO Sells 20,354 Shares of Stock - MarketBeat

Jan 06, 2026

Jan 06, 2026

Galectin Therapeutics Faces Securities Fraud Investigation as Stock Plummets 28.9% - Intellectia AI

Jan 06, 2026

Jan 06, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin ... - Bluefield Daily Telegraph

Jan 06, 2026

Jan 06, 2026

Should I hold or sell Galectin Therapeutics Inc. stock in 20252026 world cup usa national team qualification top scorers build up play knockout prediction preview - ulpravda.ru

Jan 06, 2026

Jan 02, 2026

Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jan 02, 2026

Jan 01, 2026

Galectin Therapeutics reveals promising NAVIGATE trial results - MSN

Jan 01, 2026

Jan 01, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jan 01, 2026

Jan 01, 2026

Inflation Data: Why Galectin Therapeutics Inc stock could rally in 2025Market Movers & Reliable Breakout Forecasts - moha.gov.vn

Jan 01, 2026

Jan 01, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors ofGALT - PR Newswire

Jan 01, 2026

Dec 31, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeutics Inc. (GALT) Investors to Inquire about Securities Investigation - ACCESS Newswire

Dec 31, 2025

Dec 30, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Investors to Reach Out - ACCESS Newswire

Dec 30, 2025

Dec 29, 2025

GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm - The AI Journal

Dec 29, 2025

Dec 24, 2025

Galectin Therapeutics: Runway With Convertible Financing But Dilution Overhang Remains - Seeking Alpha

Dec 24, 2025

Dec 24, 2025

Freeman Kevin D, director at Galectin Therapeutics, buys $19,514 in shares - Investing.com Australia

Dec 24, 2025

Dec 24, 2025

Eldred Kary, director at Galectin Therapeutics, buys $2611 in stock By Investing.com - Investing.com Nigeria

Dec 24, 2025

Dec 23, 2025

Eldred Kary, Galectin Therapeutics director, buys $2.6k in shares By Investing.com - Investing.com South Africa

Dec 23, 2025

Dec 23, 2025

Freeman Kevin D, director at Galectin Therapeutics, buys $19,514 in shares By Investing.com - Investing.com South Africa

Dec 23, 2025

Dec 23, 2025

Galectin therapeutics director Kevin Freeman buys $19,514 in stock By Investing.com - Investing.com Canada

Dec 23, 2025

Dec 23, 2025

Galectin therapeutics director Kevin Freeman buys $19,514 in stock - Investing.com

Dec 23, 2025

Dec 23, 2025

Eldred Kary, Galectin Therapeutics director, buys $2.6k in shares - Investing.com

Dec 23, 2025

Dec 23, 2025

Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 By Investing.com - Investing.com Nigeria

Dec 23, 2025

Dec 23, 2025

Eldred Kary, director at Galectin Therapeutics, buys $2611 in stock - Investing.com

Dec 23, 2025

Dec 23, 2025

Freeman buys Galectin Therapeutics (GALT) shares worth $19,514 - Investing.com India

Dec 23, 2025

Dec 23, 2025

Galectin Therapeutics Director Kevin D Freeman Acquires 5,500 Shares - TradingView — Track All Markets

Dec 23, 2025

Dec 22, 2025

Why did GALT shares plummet over 30% today? - MSN

Dec 22, 2025

Dec 22, 2025

Galectin Advances Belapectin Program With FDA Feedback And Secures $10 Million Credit Line - Nasdaq

Dec 22, 2025

Dec 21, 2025

Galectin Therapeutics (GALT) price target increased by 83.33% to 11.22 - MSN

Dec 21, 2025

Dec 21, 2025

Galectin Therapeutics Earnings Notes - Trefis

Dec 21, 2025

Dec 20, 2025

Galectin Therapeutics (GALT) Price Target Increased by 83.33% to 11.22 - Nasdaq

Dec 20, 2025

Dec 19, 2025

Why Galectin Therapeutics Inc. stock is favored by pension fundsJuly 2025 Snapshot & Weekly Top Gainers Trade List - Улправда

Dec 19, 2025